{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:00:51Z","timestamp":1788782451088,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thymectomy is a well-established treatment in anti-AChR generalized myasthenia gravis (gMG) patients aged 18\u201350\u00a0years. However, the MGTX trial failed to prove an additional benefit of thymectomy in late-onset MG (LOMG) patients and studies conducted so far have shown controversial results. The primary aim of this study was to assess the safety and effectiveness of thymectomy in LOMG patients compared to medical therapy alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an observational retrospective case\u2013control study of LOMG patients followed at the MG Clinic of Pisa University Hospital from 1996 to 2024. Inclusion criteria were: diagnosis of non-thymomatous gMG with anti-AChR antibodies; age at onset\u2009\u2265\u200950\u00a0years, and minimum follow-up of 12\u00a0months. The cumulative incidence of disease remission between the thymectomy and the conservative group was compared with Kaplan\u2013Meier analysis with log-rank test and the Cox regression model was used to estimate the effect of thymectomy on achieving remission after adjustment for confounding variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among our population of 127 LOMG patients, 87 patients underwent thymectomy, while 40 patients received medical treatment only. When evaluating neurological outcomes at the last follow-up, the thymectomy group had a 3.25-fold (HR\u2009=\u20093.25, 95% CI 1.31\u20138.1) increased probability of achieving disease remission than the conservative group, after adjustment for confounding variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that thymectomy may be a feasible and potentially beneficial therapeutic option in this MG subgroup, possibly increasing the likelihood of disease remission without ongoing immunosuppressive therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-025-13424-2","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:42:17Z","timestamp":1761028937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term effectiveness of thymectomy in late-onset myasthenia gravis"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7474-3681","authenticated-orcid":false,"given":"Ester","family":"Latini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelina Cristina","family":"Zirafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Cepele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Maestri Tassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"10","key":"13424_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"1","key":"13424_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1196\/annals.1405.040","volume":"1132","author":"JA Aarli","year":"2008","unstructured":"Aarli JA (2008) Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 1132(1):238\u2013243. https:\/\/doi.org\/10.1196\/annals.1405.040","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"13424_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","volume":"74","author":"A Vincent","year":"2003","unstructured":"Vincent A (2003) Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74(8):1105\u20131108. https:\/\/doi.org\/10.1136\/jnnp.74.8.1105","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"13424_CR4","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","volume":"259","author":"SA \u017divkovi\u0107","year":"2012","unstructured":"\u017divkovi\u0107 SA, Clemens PR, Lacomis D (2012) Characteristics of late-onset myasthenia gravis. J Neurol 259(10):2167\u20132171. https:\/\/doi.org\/10.1007\/s00415-012-6478-6","journal-title":"J Neurol"},{"key":"13424_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008903","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S et al (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000008903","journal-title":"Neurology"},{"issue":"5","key":"13424_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/mus.28077","volume":"69","author":"E Sechi","year":"2024","unstructured":"Sechi E, Deiana GA, Puci M et al (2024) Epidemiology of seropositive myasthenia gravis in Sardinia: a population-based study in the district of Sassari. Muscle Nerve 69(5):637\u2013642. https:\/\/doi.org\/10.1002\/mus.28077","journal-title":"Muscle Nerve"},{"issue":"4","key":"13424_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"issue":"3","key":"13424_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"13424_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/med-23-43","volume":"8","author":"W Waheed","year":"2024","unstructured":"Waheed W, Bacopulos A, Seyam M et al (2024) Physiological and pathological roles of the thymus and value of thymectomy in myasthenia gravis: a narrative review. Mediastinum 8:31\u201331. https:\/\/doi.org\/10.21037\/med-23-43","journal-title":"Mediastinum"},{"issue":"6","key":"13424_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB et al (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375(6):511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1602489","journal-title":"N Engl J Med"},{"issue":"3","key":"13424_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","volume":"18","author":"GI Wolfe","year":"2019","unstructured":"Wolfe GI, Kaminski HJ, Aban IB et al (2019) Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol 18(3):259\u2013268. https:\/\/doi.org\/10.1016\/S1474-4422(18)30392-2","journal-title":"Lancet Neurol"},{"issue":"1","key":"13424_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1468-1331.2002.00352.x","volume":"9","author":"F Romi","year":"2002","unstructured":"Romi F, Gilhus NE, Varhaug JE, Myking A, Skeie GO, Aarli JA (2002) Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Euro J Neurol 9(1):55\u201361. https:\/\/doi.org\/10.1046\/j.1468-1331.2002.00352.x","journal-title":"Euro J Neurol"},{"issue":"10","key":"13424_CR13","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.clineuro.2007.08.006","volume":"109","author":"N Kawaguchi","year":"2007","unstructured":"Kawaguchi N, Kuwabara S, Nemoto Y et al (2007) Effects of thymectomy on late-onset myasthenia gravis without thymoma. Clin Neurol Neurosurg 109(10):858\u2013861. https:\/\/doi.org\/10.1016\/j.clineuro.2007.08.006","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"13424_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s00415-019-09222-2","volume":"266","author":"SW Kim","year":"2019","unstructured":"Kim SW, Choi YC, Kim SM, Shim HS, Shin HY (2019) Effect of thymectomy in elderly patients with non-thymomatous generalized myasthenia gravis. J Neurol 266(4):960\u2013968. https:\/\/doi.org\/10.1007\/s00415-019-09222-2","journal-title":"J Neurol"},{"issue":"1","key":"13424_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13023-021-01860-y","volume":"16","author":"J Zhang","year":"2021","unstructured":"Zhang J, Chen Y, Zhang H, Yang Z, Zhang P (2021) Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis. Orphanet J Rare Dis 16(1):232. https:\/\/doi.org\/10.1186\/s13023-021-01860-y","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"13424_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70048","volume":"32","author":"J Chen","year":"2025","unstructured":"Chen J, Su C, Feng H, Kaminski HJ (2025) Can non-thymomatous late-onset myasthenia gravis benefit from thymectomy? a systematic review and meta-analysis. Eur J Neurol 32(3):e70048. https:\/\/doi.org\/10.1111\/ene.70048","journal-title":"Eur J Neurol"},{"issue":"3","key":"13424_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia gravis: association of British neurologists\u2019 management guidelines. Pract Neurol 15(3):199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126","journal-title":"Pract Neurol"},{"issue":"6","key":"13424_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","volume":"40","author":"A Evoli","year":"2019","unstructured":"Evoli A, Antonini G, Antozzi C et al (2019) Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci 40(6):1111\u20131124. https:\/\/doi.org\/10.1007\/s10072-019-03746-1","journal-title":"Neurol Sci"},{"issue":"4","key":"13424_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s13760-024-02552-7","volume":"124","author":"JL De Bleecker","year":"2024","unstructured":"De Bleecker JL, Remiche G, Alonso-Jim\u00e9nez A et al (2024) Recommendations for the management of myasthenia gravis in Belgium. Acta Neurol Belg 124(4):1371\u20131383. https:\/\/doi.org\/10.1007\/s13760-024-02552-7","journal-title":"Acta Neurol Belg"},{"key":"13424_CR20","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"13424_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK et al (2024) Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Euro J Neurol 31(5):e16229. https:\/\/doi.org\/10.1111\/ene.16229","journal-title":"Euro J Neurol"},{"issue":"6","key":"13424_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41582-020-0345-3","volume":"16","author":"C Barnett","year":"2020","unstructured":"Barnett C, Bril V (2020) New insights into very-late-onset myasthenia gravis. Nat Rev Neurol 16(6):299\u2013300. https:\/\/doi.org\/10.1038\/s41582-020-0345-3","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"13424_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/tri.13081","volume":"31","author":"A Gleiss","year":"2018","unstructured":"Gleiss A, Oberbauer R, Heinze G (2018) An unjustified benefit: immortal time bias in the analysis of time-dependent events. Transpl Int 31(2):125\u2013130. https:\/\/doi.org\/10.1111\/tri.13081","journal-title":"Transpl Int"},{"issue":"1","key":"13424_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ et al (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55(1):16\u201323. https:\/\/doi.org\/10.1212\/WNL.55.1.16","journal-title":"Neurology"},{"issue":"5","key":"13424_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM, MG COMPOSITE AND MG-QOL15 STUDY GROUP (2011) MG-ADL: still a relevant outcome measure. Muscle Nerve 44(5):727\u2013731. https:\/\/doi.org\/10.1002\/mus.22140","journal-title":"Muscle Nerve"},{"issue":"6","key":"13424_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65(6):630\u2013639. https:\/\/doi.org\/10.1002\/mus.27476","journal-title":"Muscle Nerve"},{"issue":"18","key":"13424_CR27","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB (2010) The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74(18):1434\u20131440. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e","journal-title":"Neurology"},{"issue":"1","key":"13424_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/mus.28417","volume":"72","author":"K Ruzhansky","year":"2025","unstructured":"Ruzhansky K, Li Y, Wolfe GI, Muppidi S et al (2025) Standardization of myasthenia gravis outcome measures in clinical practice: a report of the MGFA task force. Muscle Nerve 72(1):56\u201365. https:\/\/doi.org\/10.1002\/mus.28417","journal-title":"Muscle Nerve"},{"issue":"6","key":"13424_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1159\/000050579","volume":"68","author":"M De Perrot","year":"2001","unstructured":"De Perrot M, Licker M, Spiliopoulos A (2001) Factors influencing improvement and remission rates after thymectomy for myasthenia gravis. Respiration 68(6):601\u2013605. https:\/\/doi.org\/10.1159\/000050579","journal-title":"Respiration"},{"issue":"1\u20132","key":"13424_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0022-510X(03)00087-X","volume":"212","author":"R Mantegazza","year":"2003","unstructured":"Mantegazza R, Baggi F, Bernasconi P et al (2003) Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. J Neurol Sci 212(1\u20132):31\u201336. https:\/\/doi.org\/10.1016\/S0022-510X(03)00087-X","journal-title":"J Neurol Sci"},{"issue":"4","key":"13424_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/021849230301100411","volume":"11","author":"Y El-Medany","year":"2003","unstructured":"El-Medany Y, Hajjar W, Essa M, Al-Kattan K, Hariri Z, Ashour M (2003) Predictors of outcome for myasthenia gravis after thymectomy. Asian Cardiovasc Thorac Ann 11(4):323\u2013327. https:\/\/doi.org\/10.1177\/021849230301100411","journal-title":"Asian Cardiovasc Thorac Ann"},{"issue":"1","key":"13424_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejcts.2009.05.027","volume":"37","author":"MW Lin","year":"2010","unstructured":"Lin MW, Chang YL, Huang PM, Lee YC (2010) Thymectomy for non-thymomatous myasthenia gravis: a comparison of surgical methods and analysis of prognostic factors. Eur J Cardiothorac Surg 37(1):7\u201312. https:\/\/doi.org\/10.1016\/j.ejcts.2009.05.027","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"13424_CR33","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00415-015-7673-z","volume":"262","author":"A Uzawa","year":"2015","unstructured":"Uzawa A, Kawaguchi N, Kanai T et al (2015) Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. J Neurol 262(4):1019\u20131023. https:\/\/doi.org\/10.1007\/s00415-015-7673-z","journal-title":"J Neurol"},{"issue":"1","key":"13424_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.athoracsur.2010.08.041","volume":"91","author":"Z Chen","year":"2011","unstructured":"Chen Z, Luo H, Peng Y et al (2011) Comparative clinical features and immune responses after extended thymectomy for Myasthenia Gravis in patients with atrophic versus hyperplastic thymus. Ann Thorac Surg 91(1):212\u2013218. https:\/\/doi.org\/10.1016\/j.athoracsur.2010.08.041","journal-title":"Ann Thorac Surg"},{"key":"13424_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jneuroim.2017.01.005","volume":"305","author":"K Nakahara","year":"2017","unstructured":"Nakahara K, Nakane S, Nakajima M, Yamashita S, Mori T, Ando Y (2017) Effect of thymectomy for thymic atrophy in myasthenia gravis: a retrospective study on 93 patients. J Neuroimmunol 305:182\u2013185. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.01.005","journal-title":"J Neuroimmunol"},{"issue":"1","key":"13424_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/ejcts\/ezu309","volume":"48","author":"Z Mao","year":"2015","unstructured":"Mao Z, Hu X, Lu Z, Hackett ML (2015) Prognostic factors of remission in myasthenia gravis after thymectomy. Eur J Cardiothorac Surg 48(1):18\u201324. https:\/\/doi.org\/10.1093\/ejcts\/ezu309","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9","key":"13424_CR37","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1007\/s00415-024-12592-x","volume":"271","author":"A Papathanasiou","year":"2024","unstructured":"Papathanasiou A, Tench CR, Ambrose PA, Sedehizadeh S, Tanasescu R (2024) Pre-thymectomy disease severity predicts outcome in acetylcholine receptor antibody-positive generalised myasthenia gravis. J Neurol 271(9):6220\u20136226. https:\/\/doi.org\/10.1007\/s00415-024-12592-x","journal-title":"J Neurol"},{"issue":"5","key":"13424_CR38","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0022-5223(19)39268-2","volume":"82","author":"JW Rubin","year":"1981","unstructured":"Rubin JW, Ellison RG, Moore HV, Pai GP (1981) Factors affecting response to thymectomy for myasthenia gravis. J Thorac Cardiovasc Surg 82(5):720\u2013728","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"13424_CR39","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/1010-7940(89)90109-7","volume":"3","author":"G Maggi","year":"1989","unstructured":"Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E (1989) Thymectomy in myasthenia gravis *1results of 662 cases operated upon in 15 years. Eur J Cardiothorac Surg 3(6):504\u2013511. https:\/\/doi.org\/10.1016\/1010-7940(89)90109-7","journal-title":"Eur J Cardiothorac Surg"},{"issue":"2","key":"13424_CR40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/0003-4975(94)90993-8","volume":"57","author":"WH Frist","year":"1994","unstructured":"Frist WH, Thirumalai S, Doehring CB et al (1994) Thymectomy for the myasthenia gravis patient: factors influencing outcome. Ann Thorac Surg 57(2):334\u2013338. https:\/\/doi.org\/10.1016\/0003-4975(94)90993-8","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"13424_CR41","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0022-5223(96)70151-4","volume":"112","author":"MJ Mack","year":"1996","unstructured":"Mack MJ, Landreneau RJ, Yim AP, Hazelrigg SR, Scruggsa GR (1996) Results of video-assisted thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 112(5):1352\u20131360. https:\/\/doi.org\/10.1016\/S0022-5223(96)70151-4","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"13424_CR42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0003-4975(10)61951-0","volume":"39","author":"Y Monden","year":"1985","unstructured":"Monden Y, Nakahara K, Fujii Y et al (1985) Myasthenia gravis in elderly patients. Ann Thorac Surg 39(5):433\u2013436. https:\/\/doi.org\/10.1016\/S0003-4975(10)61951-0","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"13424_CR43","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/icvts\/ivv176","volume":"21","author":"Z Liu","year":"2015","unstructured":"Liu Z, Yang J, Lin L, Huang J, Jiang G (2015) Unilateral video-assisted thoracoscopic extended thymectomy offers long-term outcomes equivalent to that of the bilateral approach in the treatment of non-thymomatous myasthenia gravis. Interact Cardiovasc Thorac Surg 21(5):610\u2013615. https:\/\/doi.org\/10.1093\/icvts\/ivv176","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"1","key":"13424_CR44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.athoracsur.2003.11.040","volume":"78","author":"M Zieli\u0144ski","year":"2004","unstructured":"Zieli\u0144ski M, Ku\u017cd\u017ca\u0142 J, Szlubowski A, Soja J (2004) Comparison of late results of basic transsternal and extended transsternal thymectomies in the treatment of myasthenia gravis. Ann Thorac Surg 78(1):253\u2013258. https:\/\/doi.org\/10.1016\/j.athoracsur.2003.11.040","journal-title":"Ann Thorac Surg"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13424-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:01:09Z","timestamp":1763128869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13424-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["13424"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13424-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MG received personal fees from Alexion, UCB, Argenx and Amgen outside the submitted work. GSreceived personal fees from Biogen, Roche, Sanofi, Lupin, Sarepta, Amicus, Csl Behring, Takeda, Grifols,Alnylam outside the submitted work. CCZ are official proctors for Intuitive Surgical. MM received lectureshonoraria from Alexion and personal fees from Alexion, Argenx, UCB, Johnson & Johnson, Idorsia outsidethe submitted work.EL, AC, SR, GR, RR have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was granted by Local Ethical Committee CEAVNO (Application ID: 19211) and the study was conducted in accordance with the Declaration of Helsinki and its amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"714"}}